长风药业(02652.HK)：就建议实施H股全流通向中国证监会备案

Core Viewpoint - Changfeng Pharmaceutical (02652.HK) has submitted a filing application to the China Securities Regulatory Commission (CSRC) for the proposed implementation of full circulation of H-shares, converting 107,408,422 unlisted domestic shares into H-shares [1] Group 1 - The company plans to convert 107,408,422 unlisted shares into H-shares on a one-to-one basis [1] - The conversion will be subject to the completion of all filing requirements, including approval from the CSRC and the Stock Exchange of Hong Kong [1] - Upon approval, the converted H-shares will be listed and traded on the Stock Exchange of Hong Kong [1]